January 13, 2026 Sweden
BioStock: Diamyd Medical - a Swedish example of Nobel Prize science in action
In an interview with BioStock, board member Karin Rosén discusses how Nobel Prize–recognized research on peripheral immune tolerance underpins Diamyd Medical’s strategy and its relevance for autoimmune diabetes. She also outlines what preserving patients’ own insulin production could mean for disease modification as the company approaches the interim phase III DIAGNODE-3 readout in March 2026.
Read the article here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.